

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
("Ascendis Health" or "the Company")



DISPENSATION RECEIVED ON 60 DAY RULE TO DISPATCH CIRCULAR

Shareholders are referred to the announcement released on 1 February 2022 regarding the proposed disposal by Ascendis Health SA Holdings Proprietary Limited, a wholly-owned subsidiary of Ascendis Health, of its direct and indirect interests in the entities through which the businesses known as "Pharma", "Skin" and "Medical" operate (collectively, "the Disposals").

Shareholders are advised that the Company has, in relation to the proposed Disposals, received dispensation from compliance with paragraph 9.20(b) of the JSE Limited Listings Requirements, which stipulates that a company must dispatch a circular to its shareholders containing a notice of general meeting to obtain their approval for a transaction within 60 days of the date of announcement of such transaction. Shareholders are further advised that a circular containing details pertaining to the Disposals, as well as a notice of general meeting to obtain the approval of shareholders for the transactions, is expected to be dispatched on or about 31 May 2022.

The board of directors of the Company ("the **Board**") accepts responsibility for the information contained in this announcement as it pertains to Ascendis Health. To the best of the Board's knowledge and belief, the information contained in this announcement as it pertains to Ascendis Health is true and nothing has been omitted which is likely to affect the importance of such information.

5 April 2022
Bryanston

Sponsor



Questco Corporate Advisory Proprietary Limited